MBHB Partner Kevin Noonan Authors Pharmaceutical Executive Article, “The True Nature of Danger Behind IP Waiver Proposal”
July 13, 2022
McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D., writes about how the WTO’s COVID vaccine IP waiver could impact innovation and the protection of trade secrets in Pharmaceutical Executive. View the article.
